Veracyte SEC Filings

Veracyte (VCYT) insider activity: The company’s VP and Chief Accounting Officer reported open‑market sales of common stock. On 11/07/2025, 5,818 shares were sold at a weighted average price of $40.2078. On 11/10/2025, 5,102 shares were sold at a weighted average price of $42.3321. Following these transactions, beneficial ownership stood at 38,745 shares.

The filing notes that each weighted average reflects multiple trades within disclosed price ranges, with detailed breakdowns available upon request.

Veracyte (VCYT) reported an insider transaction by its SVP, General Counsel. On 11/05/2025, the officer sold 6,466 shares of common stock at $40 per share, coded as an open market sale (S). Following the sale, the reporting person beneficially owned 82,973 shares, held directly. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2024.

Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the insider exercised stock options for 30,000 shares at exercise prices of $5.28, $7.94, and $7.60, then sold 43,196 shares in multiple trades at weighted average prices ranging from $41.10 to $46.40. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2024.

Following the transactions, the insider directly beneficially owns 30,468 shares. The options exercised were fully vested, tied to grants expiring on 06/20/2026, 06/07/2027, and 06/07/2028.

Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the reporting person sold 9,674 shares of common stock, coded “S”. The weighted average sale price was $40.0239, with individual trades ranging from $40.00 to $40.70.

Following the sale, the insider beneficially owned 13,554 shares, held directly. The transactions were made under a Rule 10b5-1 trading plan adopted on August 20, 2024, which pre‑sets trading instructions.

Veracyte, Inc. (VCYT) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 7,000 shares of common stock at $41 on 11/05/2025, marked with transaction code S. The filing notes the trades were made under a Rule 10b5-1 plan adopted on August 13, 2024.

After the sale, the officer beneficially owns 126,158 shares, held directly.

Veracyte, Inc. reported stronger Q3 2025 results, with total revenue of $131.9 million, up from $115.9 million a year ago. Testing revenue rose to $127.8 million, while product revenue was $3.3 million and biopharmaceutical and other revenue was $0.8 million. Gross profit increased to $91.3 million. Net income was $19.1 million versus $15.2 million last year, and diluted EPS was $0.24 versus $0.19.

Operating expenses were $68.3 million. Other income (loss), net was a loss of $4.1 million, reflecting a $6.7 million loss on deconsolidation of the French subsidiary in August 2025. For the nine months, operating cash flow was $83.7 million, up from $50.6 million. The balance sheet showed cash and cash equivalents of $315.6 million, short‑term investments of $50.9 million, and stockholders’ equity of $1.26 billion as of September 30, 2025. Medicare and UnitedHealthcare represented 33% and 14% of Q3 revenue, respectively. Shares outstanding were 79,049,173 as of October 31, 2025.

Veracyte, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.

The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically so stated.

Veracyte, Inc. (VCYT) officer Jonathan Wygant, VP and Chief Accounting Officer, reported an equity award on Form 4. On 10/28/2025, he acquired 2,886 shares of common stock at $0 under transaction code A, reflecting a restricted stock unit grant. Following the transaction, his beneficial ownership stands at 49,665 shares, held directly.

The filing notes the RSUs were awarded on October 28, 2025 and vest in full on the first anniversary of the grant date, subject to his continued employment.

Veracyte, Inc. insider Phillip G. Febbo sold 8,349 shares of common stock on 10/06/2025 at a weighted average price of $36.0174, reducing his beneficial ownership to 92,441 shares. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on 09/04/2024, and individual sale prices ranged from $35.82 to $36.28. The Form 4 was signed by an attorney-in-fact on 10/07/2025. No options or derivative transactions were reported.